Method and System to Improve the Health of a Person's Skin Microbiome

• US 20170119827A1
• Filed: 01/11/2017
• Published: 05/04/2017
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik
• Inventors: Kovarik, Joseph E.
• Granted Patent: US 10,111,913 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/11 Medicinal preparations comprising living procariotic cells
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1758 p53

Abstract

Compositions, systems and methods of improving the health of the microbiome of an individual'"'"'s skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.

Claims

1. A method for altering the microbiome of an individual'"'"'s skin, comprising:

administering to a region of the skin of an individual an effective amount of a bacterial formulation, the individual being a newborn and the step of administering performed within the first 6 hours of the newborn'"'"'s birth, said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto the newborn'"'"'s skin;

wherein the bacterial formulation comprises at least two of the bacteria selected from the group consisting of;

Prevotella;

Lactobacillus johnsonii;

Bacteroides fragilis;

Lactobacillus ruminus;

L. infantitis;

Propionibacterium; and

Staphylococcus aureus.

2. The method as set forth in claim 1, further comprising administering to the region of the skin a bacteria selected from the group consisting of Nitrosomonas eutropha.

3. The method as set forth in claim 1, further comprising adjusting the equilibrium of a bacterial population of the region of the skin of the individual to increase the number of Propionibacterium bacteria and to decrease the number of Staphylococcus bacteria on the individual'"'"'s skin in said region.

4. The method as set forth in claim 1, wherein the bacterial formulation includes the bacteria Staphylococcus aureus that has been modified by employing a CRISPR-Cas or Cpf1 system to interfere with S. aureus virulence regulation involving an Agr quorum-sensing signaling molecule.

5. The method as set forth in claim 1, wherein the bacterial formulation comprises a bacteria that has a tropism specific for the human species.

6. The method as set forth in claim 1, wherein the bacterial formulation comprises at least two of the bacteria selected from the group consisting of:

Prevotella;

Lactobacillus johnsonii;

Bacteroides fragilis, Lactobacillus ruminus and L. infantitis.

7. The method as set forth in claim 1, wherein the bacteria is an ammonia oxidizing bacteria.

8. The method as set forth in claim 1, wherein the region of the skin is the scalp.

9. The method as set forth in claim 1, wherein the bacteria has been modified by CRISPR-Cas or CRISPR-Cpf1 to delete a functional virulence factor from the bacteria.

10. The method as set forth in claim 1, further comprising administering to the skin a bacteria that produces tomatidine.

11. The method as set forth in claim 1, further comprising administering to the skin a bacteria that produces p53.

12. The method as set forth in claim 1, wherein a CRISPR-Cas or CRISPR-Cpf1 system is employed to insert a gene for the production of tomatidine into at least one of the bacteria in the bacterial formulation.

13. The method as set forth in claim 1, wherein a CRISPR-Cas or CRISPR-Cpf1 system is employed to insert one or more genes into the bacteria comprising the bacterial formulation to facilitate the oxidizing of ammonia by the bacteria.

14. The method as set forth in claim 1, further comprising administering to the individual'"'"'s skin a prebiotic that comprises a nutrient source for the bacteria that is assimilated by the bacteria but which is not digestible by the individual.

15. The method as set forth in claim 1, wherein the bacterial formulation includes bacteria selected from the group consisting of Nitrosomonas eutropha and Propionibacterium.

16. The method as set forth in claim 1, further comprising adjusting the equilibrium of a bacterial population of the region of the skin of the individual to increase the number of Propionibacterium bacteria and to decrease the number of Staphylococcus bacteria on the individual'"'"'s skin in said region.

17. The method as set forth in claim 1, further comprising administering to the skin an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus, and Trichinella spiralis.

18. The method as set forth in claim 1, wherein the bacterial formulation includes at least one arabinogalactan.

19. The method as set forth in claim 1, wherein the bacterial formulation includes at least one of the following:

L. infantitis, L. johnsonii.

20. The method as set forth in claim 1, wherein the bacterial formulation includes at least one bacteria modified via a CRISPR-Cas system to express a gene encoding interferon regulatory factor 4.